Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors
Open Access
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Over-Expression of EphA2 and EphrinA-1 in Human Gastric Adenocarcinoma and Its Prognostic Value for Postoperative PatientsDigestive Diseases and Sciences, 2008
- Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular systemThe Journal of Pathology, 2006
- Expression of EphA2 and Ephrin A-1 in Carcinoma of the Urinary BladderClinical Cancer Research, 2006
- The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomasGynecologic Oncology, 2005
- EphA2 as a Novel Molecular Marker and Target in Glioblastoma MultiformeMolecular Cancer Research, 2005
- Monoclonal antibody therapy of cancerNature Biotechnology, 2005
- CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cellsJournal of Immunological Methods, 2005
- Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA DeliveryCancer Research, 2005
- EphA2 Receptor Tyrosine Kinase as a Promising Target for Cancer TherapeuticsCurrent Cancer Drug Targets, 2005
- Enhanced Natural Killer Cell Binding and Activation by Low-Fucose IgG1 Antibody Results in Potent Antibody-Dependent Cellular Cytotoxicity Induction at Lower Antigen DensityClinical Cancer Research, 2005